美泊利单抗减少哮喘气道嗜酸性粒细胞数量但不改变其功能表型
该研究在轻度过敏性哮喘患者中进行分段过敏原激发,比较单次静脉注射750 mg美泊利单抗前后血液、肺泡灌洗液和支气管活检中嗜酸性粒细胞的数量与表型。美泊利单抗消除了过敏原诱导的外周血嗜酸性粒细胞升高及IL-3受体表达,但气道嗜酸性粒细胞增多和嗜酸性粒细胞过氧化物酶沉积仅被削弱而未消除,且气道嗜酸性粒细胞的活化表型在治疗后维持不变。
要点
- 美泊利单抗减少气道嗜酸性粒细胞数量,但未完全消除气道嗜酸性粒细胞增多。
- 气道嗜酸性粒细胞的活化标志物和过氧化物酶释放未受美泊利单抗显著影响。
- 这或可解释IL-5中和减少但不完全消除哮喘急性发作。
核心结论
- 美泊利单抗减少气道嗜酸性粒细胞数量,但对气道嗜酸性粒细胞活化标志物影响有限,提示这些细胞仍保留功能。
研究设计与样本
- 在轻度过敏性哮喘参与者中,于单次静脉注射750 mg美泊利单抗前和1个月后行分段过敏原激发,激发后48小时检查血液、肺泡灌洗液和支气管活检中的嗜酸性粒细胞。
主要发现
- 未用美泊利单抗的分段激发诱导循环嗜酸性粒细胞升高、肺泡灌洗液嗜酸性粒细胞增多和支气管黏膜嗜酸性粒细胞过氧化物酶沉积。
- 美泊利单抗消除过敏原诱导的循环嗜酸性粒细胞升高和IL-3受体表达,气道嗜酸性粒细胞增多和过氧化物酶沉积被削弱但未消除。
- 美泊利单抗治疗前,肺泡灌洗液嗜酸性粒细胞表面IL-3和粒细胞-单核细胞集落刺激因子受体、CD69、CD44、CD23高于血液嗜酸性粒细胞,而IL-5和嗜酸性粒细胞趋化因子受体降低。
- 美泊利单抗治疗后,肺泡灌洗液嗜酸性粒细胞表面标志物指示的活化表型及支气管黏膜嗜酸性粒细胞过氧化物酶释放维持不变。
临床怎么用
- 临床使用美泊利单抗时需注意其减少气道嗜酸性粒细胞数量但不完全抑制其功能,可能影响急性发作的完全控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Mepolizumab, an IL-5-blocking antibody, reduces exacerbations in patients with severe eosinophilic asthma. Mepolizumab arrests eosinophil maturation; however, the functional phenotype of eosinophils that persist in the blood and airway after administration of IL-5 neutralizing antibodies has not been reported. OBJECTIVES: To determine the effect of anti-IL-5 antibody on the numbers and phenotypes of allergen-induced circulating and airway eosinophils. METHODS: Airway inflammation was elicited in participants with mild allergic asthma by segmental allergen challenge before and 1 month after a single intravenous 750-mg dose of mepolizumab. Eosinophils were examined in blood, bronchoalveolar lavage, and endobronchial biopsies 48 hours after challenge. MEASUREMENTS AND MAIN RESULTS: Segmental challenge without mepolizumab induced a rise in circulating eosinophils, bronchoalveolar lavage eosinophilia, and eosinophil peroxidase deposition in bronchial mucosa. IL-5 neutralization before allergen challenge abolished the allergen-induced rise in circulating eosinophils and expression of IL-3 receptors, whereas airway eosinophilia and eosinophil peroxidase deposition were blunted but not eliminated. Before mepolizumab treatment, bronchoalveolar lavage eosinophils had more surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD23 and decreased IL-5 and eotaxin receptors than blood eosinophils. This activation phenotype indicated by bronchoalveolar lavage eosinophil surface markers, as well as the release of eosinophil peroxidase by eosinophils in the bronchial mucosa, was maintained after mepolizumab. CONCLUSIONS: Mepolizumab reduced airway eosinophil numbers but had a limited effect on airway eosinophil activation markers, suggesting that these cells retain functionality. This observation may explain why IL-5 neutralization reduces but does not completely eradicate asthma exacerbations. Clinical trial registered with www.clinicaltrials.gov (NCT00802438).
引用
- Kelly EA, Esnault S, Liu LY, et al. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Am J Respir Crit Care Med. 2017. PMID: 28862877. doi:10.1164/rccm.201611-2234OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。